Article Text

Download PDFPDF
CP-126 Effectiveness and safety assessment of direct acting antiviral in the treatment of chronic hepatitis C virus infection
  1. MC Serrano Vicente1,
  2. A Escolano Pueyo1,
  3. MC Viñuales Armengol1,
  4. N Allué Fantova1,
  5. L Torres Sopena2,
  6. MP Amador Rodríguez1
  1. 1San Jorge Hospital, Pharmacy Service, Huesca, Spain
  2. 2San Jorge Hospital, Microbiology Service, Huesca, Spain


Background Direct acting antivirals (DAA) have become the elective treatment for chronic hepatitis C virus (HCV) infection but definitive data regarding routine medical practice are still limited.

Purpose To assess the effectiveness and safety of DAA in the treatment of chronic HCV infection in a 300 bed general hospital.

Material and methods This was an observational, retrospective, descriptive study conducted from December 2014 to February 2016. Inclusion criteria: HCV patients who started treatment with dasabuvir+paritaprevir–ombitasvir–ritonavir (DAS+OMBI/PARI/r), simeprevir (SIM), sofosbuvir+daclatasvir (SOF+DACL) or sofosbuvir–ledipasvir (SOF/LD) during the study period. Exclusion criteria: patients not achieving 12 weeks of treatment during the study period. Effectiveness variables: gender and age, genotype, fibrosis degree (F1–F4), HIV coinfection, basal viral load (VL), fast virologic response (FVR, VL ≤15 IU/mL) at week 4, VL at the end of treatment and sustained virological response (SVR) at week 12 post-treatment. Safety variables: adverse drug reactions (ADRs) and detected drug–drug interactions (DIs). Data were collected from the pharmaceutical managing programme, Farmatools, and from clinical reports, and were analysed using the SPSS statistical package.

Results 40 patients were included (30 men). Mean age: 55±2.36 years. 15 naïve patients (37.5%), 14 (35%) were HIV coinfected. Fibrosis degree: 21 F4 (52.5%), 11 F3 (27.5%) and 8 F1–F2. HCV genotype: 29 genotype 1 (72.5%), 6 genotype 4 (15%) and 5 genotype 3 (12.5%). 23 patients were treated with SOF/LDV (57.5%), 6 with DAS+OMBI/PARI/r (15%), 8 with SOF+DACL (20%) and 3 with SIM (7.5%). Effectiveness: 28 patients (70%) had basal VL >800 000 IU/mL. 31 patients (77.8%) achieved FVR. 100% achieved undetectable VL at the end of treatment. 34 (85%) patients maintained undetectable VL at 12 week post-treatment, 5 patients did not have VL determined and 1 rebounded (VL >800 000 IU/mL, HIV coinfected). 34 patients (85%) had no ADRs, 4 had gastrointestinal ADRs, 3 had asthenia, 2 had a mild allergic reaction and 1 had dizziness. DIs were detected with home medication in 17 patients: 12 with proton pump inhibitors, 5 with statins and 2 with oral antidiabetics and digoxin.

Conclusion DAAs represent a great advance in HCV treatment. In our study, 100% of patients achieved undetectable VL at the end of the treatment and a high rate of SVR at week 12. DAAs are well tolerated but they require pharmacist intervention to avoid DIs.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.